Manfred Kopf

Title: Manfred Kopf: Innovator in Chimeric Antigen Receptors

Introduction

Manfred Kopf is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of immunology, particularly in the development of chimeric antigen receptors. With a total of 3 patents, his work has the potential to impact therapeutic strategies in cancer treatment.

Latest Patents

Kopf's latest patents focus on chimeric antigen-receptor polypeptide heterodimers. These inventions comprise two polypeptides, where one contains an extracellular part of the major histocompatibility complex I alpha chain, and the other contains a 32-microglobulin domain. Alternatively, one polypeptide may contain an extracellular part of the major histocompatibility complex II alpha chain, while the other contains a major histocompatibility complex II beta chain. One of the polypeptides includes a transmembrane domain, a hinge region, and an intracellular domain of the T cell receptor alpha chain. The other polypeptide contains similar features along with an antigen-peptide covalently linked to the extracellular MHC domain. Additionally, the invention relates to a method for identifying a TCR recognizable peptide sequence using the heterodimer.

Career Highlights

Throughout his career, Manfred Kopf has worked with prestigious organizations such as ETH Zurich and Merck Sharp & Dohme Corp. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Kopf has collaborated with notable colleagues, including Jan Kisielow and Franz-Josef Obermair. These partnerships have further enriched his research and innovation in the field of immunology.

Conclusion

Manfred Kopf's contributions to the development of chimeric antigen receptors highlight his role as a significant innovator in the field. His patents and collaborations reflect a commitment to advancing medical science and improving therapeutic options for patients.